Esprit BTK Post-Approval Study

Trial details

Who runs it

Abbott Medical Devices

Trial code

NCT06656364

Record updated

25 March 2026

Original description

The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in a real-world setting. The clinical investigation will be conducted at up to 50 sites in the United States (US) and additional sites may be added outside of the US (OUS). Approximately 200 patients with a minimum of 50% of patients in the US will be registered in the clinical investigation.Read full original descriptionShow less

Esprit BTK Post-Approval Study (Esprit BTK PAS)

The Esprit BTK PAS is a prospective, single-arm, multi-center observational study to assess the continued safety and effectiveness of the Esprit™ BTK Everolimus Eluting Resorbable Scaffold System under commercial use, in patients with diseased infrapopliteal lesions causing CLTI (Chronic Limb-Threatening Ischemia) in a real-world setting. The clinical investigation will be conducted at up to 50 sites in the United States (US) and additional sites may be added outside of the US (OUS). Approximately 200 patients with a minimum of 50% of patients in the US will be registered in the clinical investigation.

Inclusion: General Inclusion Criteria; Subject must provide written informed consent prior to any study-specific procedures which are not considered standard of care at the site; Informed consent can be obtained up to 3 days post-procedure or prior to discharge whichever comes first; Subject, or a legally acceptable representative must provide written informed consent per site IRB/EC requirements; Subject must be at least 18 years of age; Subject has evidence of symptomatic Chronic Limb-Threatening Ischemia (CLTI) with infrapopliteal lesions; Anatomic Inclusion Criteria; Subjects who have lesion(s) in an infrapopliteal vessel with reference vessel diameter ≥ 2.5 mm and ≤ 4.0 mm; Target lesion(s) must have ≥ 70% stenosis, per visual assessment at the time of the procedure. If needed, quantitative imaging (angiography and intravascular imaging) can be used to aid accurate sizing of the vessels.

Exclusion: General Exclusion Criteria; Subjects who have contraindications to the Esprit BTK System per the instruction for use (IFU); Subject is currently participating in another clinical investigation that has not yet completed its primary endpoint; Subject or Legally Acceptable Representative (LAR) is unable or unwilling to provide written consent prior to enrollment; Subject with life expectancy ≤ 1 year; Subject with an unsalvageable limb (as per physician assessment at the time of the index procedure), who is likely to get a below-the-knee amputation; Anatomic Exclusion Criteria; Subject has in-stent restenosis in the target vessel or requires a metallic stent as part of a planned treatment or a bailout in the target vessel during the index procedure; Subject had been previously treated with Esprit BTK Scaffold(s) within the past 30 days in the same vessel.

ClinicalTrials.gov NCT06656364